Furthermore, despite the use of PD-1/PD-L1 blockade, which is the standard first-line treatment for non-small cell lung cancer, numerous patients with advanced cancer develop drug resistance and experience disease progression because of the immunosuppressive microenvironment [15]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.